Re: Placement of SpaceOAR hydrogel spacer for prostate cancer patients treated with iodine‐125 low‐dose‐rate brachytherapy

2020 ◽  
Vol 27 (5) ◽  
pp. 473-473 ◽  
Author(s):  
Hamed Ghaffari
Keyword(s):  
Prostate Cancer ◽  
Dose Rate ◽  
Cancer Patients ◽  
Low Dose ◽  
Low Dose Rate ◽  
Iodine 125 ◽  
Spaceoar Hydrogel ◽  
Low Dose Rate Brachytherapy

Placement of Space OAR hydrogel spacer for prostate cancer patients treated with iodine‐125 low‐dose‐rate brachytherapy

2019 ◽  
Vol 27 (1) ◽  
pp. 60-66 ◽  
Author(s):  
Masashi Morita ◽  
Takashi Fukagai ◽  
Kidai Hirayama ◽  
Jin Yamatoya ◽  
Tetsuo Noguchi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Dose Rate ◽  
Cancer Patients ◽  
Low Dose ◽  
Low Dose Rate ◽  
Iodine 125 ◽  
Low Dose Rate Brachytherapy

PP-0157 Long-term Outcomes of Prostate Cancer Patients treated with Low Dose Rate Brachytherapy

2021 ◽  
Vol 158 ◽  
pp. S120-S122
Author(s):  
T. McMullan ◽  
B. Nailon ◽  
D. McLaren ◽  
W. Keough ◽  
A. Law ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Dose Rate ◽  
Cancer Patients ◽  
Low Dose ◽  
Long Term Outcomes ◽  
Low Dose Rate ◽  
Low Dose Rate Brachytherapy

Efficacy of tadalafil against lower urinary tract symptoms after low-dose-rate brachytherapy in prostate cancer patients

2018 ◽  
Vol 12 (3) ◽  
pp. 223-227
Author(s):  
T Saito ◽  
T Minagawa ◽  
T Ogawa ◽  
O Ishizuka
Keyword(s):  
Prostate Cancer ◽  
Urinary Tract ◽  
Dose Rate ◽  
Cancer Patients ◽  
Lower Urinary Tract ◽  
Low Dose ◽  
Low Dose Rate ◽  
Urinary Tract Symptoms ◽  
Low Dose Rate Brachytherapy ◽  
Lower Urinary

Objectives: This study was performed to evaluate the effects of addition of tadalafil to tamsulosin in the treatment of brachytherapy patients with lower urinary tract symptoms (LUTS). Methods: Localized prostate cancer patients who developed LUTS after low-dose-rate brachytherapy (LDR-BT) were first treated with alpha-1 blockers (tamsulosin, 0.2 mg per day). Those still suffering from LUTS were additionally treated with phosphodiesterase type 5 inhibitor (tadalafil, 5 mg/day). LUTS was evaluated by the International Prostate Symptom Score (IPSS), IPSS Quality of Life (QOL) score, Overactive Bladder Symptom Score (OABSS), and the International Index of Erectile Function 5 (IIEF5) score before brachytherapy, before treatment with tadalafil, and after three months of treatment with tadalafil. Results: Twenty-three patients were enrolled in the study. Each subscore of the IPSS (storage symptom, voiding symptom, and postvoiding symptom) and the QOL score improved, but OABSS and IIEF5 did not show significant recovery after addition of tadalafil treatment. When patient characteristics and each question score were surveyed, time from seed implantation until treatment with tadalafil showed the strongest correlation with recovery. Conclusions: Addition of tadalafil to tamsulosin treatment was effective against LUTS in localised prostate cancer patients after brachytherapy. Evidence level: 2b

Sector analysis of dosimetry of prostate cancer patients treated with low-dose-rate brachytherapy

Brachytherapy ◽  
2014 ◽  
Vol 13 (4) ◽  
pp. 369-374 ◽  
Author(s):  
Nicola J. Nasser ◽  
Yinkun Wang ◽  
Jette Borg ◽  
Elantholi P. Saibishkumar
Keyword(s):  
Prostate Cancer ◽  
Dose Rate ◽  
Cancer Patients ◽  
Low Dose ◽  
Low Dose Rate ◽  
Sector Analysis ◽  
Low Dose Rate Brachytherapy
Sign in / Sign up

Export Citation Format

Share Document